HE YEAR in review marks significant advancements in the field of cardiovascular engineering. Exciting developments towards new therapies arose from cardiovascular tissue engineering and from new mechanistic insight into the function of the cardiovascular system in heath and disease obtained by experimentation as well as modeling and simulation. Below is a brief review of these new developments.
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In vasculogenesis and angiogenesis, vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB) and transforming growth factor-b1 (TGF-b1) serve as key bio-signaling molecules for inducing stable and functional networks of blood vessels. These factors are attached to the extracellular matrix and maintain spatio-temporal gradients that regulate vessel density, size and distribution. The study by Freeman and Cohen [1] presented a tissue-engineering scaffold capable of sequentially delivering these three angiogenic factors. The scaffold consisted of alginate-sulfate/alginate, wherein VEGF, PDGF-BB, and TGF-b1 were bound. Factor release rate from the scaffold was correlated with the equilibrium binding constants of the factors to the matrix, thus enabling the sequential delivery of VEGF, PDGF-BB and TGF-b1. After subcutaneous implantation for one and three months in rats, the blood vessel density and percentage of mature vessels were threefold greater in the triple factor-bound scaffolds than in untreated scaffolds. Moreover, vascularization within the triple factor-bound scaffolds was superior to that found in scaffolds delivering only basic fibroblast growth factor. Application of this novel scaffold is expected to be extended to the combined delivery of additional angiogenic factors or combinations of growth factors active in different tissue regeneration processes. Tissue engineering of heart valves represents a new experimental concept to fabricate viable and functional heart valve tissue from autologous cells. The study by Schaefermeier et al. [2] developed a new fabrication technique for 3-dimensional scaffolds for tissue engineering of human heart valve tissue. A human aortic homograft was scanned with an X-ray computer tomograph. The data derived from the X-ray tomogram were processed by a computer-aided design program to reconstruct the human heart valve in three dimensions. Based on this stereolithographic model, a silicone valve model resembling a human aortic valve was generated. Taking advantage of the thermoplastic properties of polyglycolic acid as scaffold material, the authors molded a three-dimensional (3-D) scaffold for the tissue engineering of human heart valves. The newly developed technique allows the fabrication of custom-made, patient-specific polymeric cardiovascular scaffolds without requiring any suture materials. These tissue-engineered heart valve constructs have the potential to grow and to remodel, which would be an important advantage especially for pediatric patients requiring heart valve replacement early in life.
The natural, anisotropic structure of healthy cardiac tissue guides the coordinated electrical activation and mechanical contraction of the heart. Abnormalities in cardiac structure caused by remodeling associated with heart disease or by congenital defects are known to affect the initiation, maintenance, and termination of lethal cardiac arrhythmias. Understanding how normal and abnormal micro-and macroscopic tissue structure contributes to the electrical function and dysfunction of the heart is therefore of critical importance in the development of antiarrhythmia therapies. Systematic studies of cardiac structure-function relationships are hindered by the intrinsic complexity and variability of in vivo and ex vivo model systems. The study by Badie and Bursac [3] presented a reproducible cell culture system that can accurately replicate the realistic microstructure of native cardiac tissues. Using cell micropatterning techniques, cultured cardiomyocytes at micro-1937-3333/$26.00 © 2009 IEEE and macroscopic spatial scales were aligned to follow local directions of cardiac fibers in murine ventricular cross sections, as measured by high-resolution diffusion tensor magnetic resonance imaging. To elucidate the roles of ventricular tissue microstructure in macroscopic impulse conduction, the authors optically mapped membrane potentials in micropatterned cardiac cultures with realistic tissue boundaries and natural cell orientation, cardiac cultures with realistic tissue boundaries but random cell orientation, and standard isotropic monolayers. The realistic variations in intramural microstructure created unique spatial signatures in micro-and macroscopic impulse propagation within ventricular cross-section cultures. This novel in vitro model system is expected to help bridge the existing gap between experimental structure-function studies in standard cardiac monolayers and intact heart tissues.
Fibroblasts represent the largest-in-number cell population in the healthy heart. Their primary function is to maintain extracellular matrix homeostasis through highly regulated synthesis and degradation of collagen. The year in review marks an increased interest in the role of fibroblasts in the heart. Although fibroblasts are not excitable cells, direct interaction with the excitable myocytes may affect electrical function in the heart. Specifically, in fibrotic hearts, tissue regions rich in fibroblasts and deposited collagen have been shown to adversely affect electrical conduction by causing delayed activations, blocking conduction, and anchoring reentrant waves. Understanding how electrotonic loading of cardiomyocytes by fibroblasts alters cardiac impulse conduction may be highly relevant to heart fibrosis. In the study by Mc Spadden et al. [4] , the authors optically mapped electrical propagation in confluent, aligned neonatal rat cardiac monolayers electrotonically loaded with cardiac fibroblasts or HEK-293 cells genetically engineered to overexpress the gap junction proteins connexin-43 or connexin-45. The study found that neonatal rat ventricular fibroblasts expressed connexin-45 rather than connexin-43 or connexin-40, weakly coupled to cardiomyocytes, and, without significant depolarization of cardiac resting potential, slowed cardiac conduction to 75% of control only at high coverage densities, similar to loading effects found from HEK-293 cells expressing similar levels of connexin-45. In contrast, HEK-293 cells with connexin-43 expression similar to that of cardiomyocytes significantly decreased cardiac conduction velocity and maximum capture rate, while increasing cardiac action potential duration and cardiac resting potential. Despite the induced conduction slowing, the proportion of spontaneously active monolayers was not increased. These results demonstrate that connexin isoform and expression level are important contributors to potential electrical interactions between unexcitable cells and myocytes in cardiac tissue. This year several computer simulation studies focused on the coupling between myocytes and fibroblasts. The study by Maleckar et al. [5] examined the electrotonic coupling between atrial myocytes and fibroblasts that may contribute to the formation of an arrhythmogenic substrate, aparticularly its effect on myocyte excitability and repolarization. To represent the system, a human atrial myocyte coupled to a variable number of fibroblasts, the study employed a new ionic model of the human atrial myocyte, and a variety of membrane representations for atrial fibroblasts. Simulations elucidated effects of alterations of intercellular coupling conductance, electrophysiological fibroblast properties, and stimulation rate on the myocyte action potential. The results demonstrated that myocyte resting potential and action potential waveform are modulated strongly by the properties of coupled fibroblasts and their number, the degree of coupling, and pacing frequency. The model provided mechanistic insight into consequences of heterologous cell coupling on human atrial myocyte electrophysiology. The study by Sachse et al. [6] presented a novel approach for mathematical modeling of electrical conduction in 2-D and 3-D cardiac tissue composed of myocytes, fibroblasts, and extracellular space. The model was an extension of established cardiac bidomain models with added description of fibroblasts. In simulations of plane waves, increased myocyte-fibroblast coupling and fibroblast-myocyte ratio reduced peak voltage and maximal upstroke velocity of myocytes as well as amplitudes and maximal downstroke velocity of extracellular potentials. These results suggest that fibroblast coupling becomes relevant for small intra-myocyte and/or large intra-fibroblast conductivity.
An important novel computer simulation study into single ionic channel function and gating was performed by Silva et al. [7] , where molecular dynamics and electrophysiological simulations were combined to link molecular structure to function. Specifically, the authors performed multiscale molecular dynamics and continuum electrostatics calculations to simulate a cardiac channel gating and its alteration by mutations that cause arrhythmias and sudden death. An all-atom model of the -subunit KCNQ1 was used to calculate electrostatic energies during gating. Whole-cell simulations show that mutations cause action potential and ECG QT interval prolongation, consistent with clinical phenotypes. This framework allows integration of multiscale observations to study the molecular basis of excitation and its alteration by disease. Detailed understanding of relationships between ion channel movement during gating, its function as a carrier of transmembrane ionic current, and its role in the whole-cell action potential is necessary for the development of effective genetic/molecular therapies and specific drug treatment of disease states that involve abnormal electrical function of excitable tissues.
Finally, two studies examined the possibilities for novel approaches to low-voltage termination of arrhythmias in the heart. Electrical therapies for terminating arrhythmias in the heart currently fall into two categories: antitachycardia pacing and cardioversion/defibrillation. Antitachycardia pacing uses low-intensity pacing stimuli delivered via a single electrode and is effective for terminating slow tachycardias. In contrast, cardioversion/defibrillation uses a single high-voltage shock to terminate the arrhythmia, but the high voltage produces undesirable side effects. The study by Ripplinger et al. [8] aimed to demonstrate that the cardioversion threshold for ventricular tachycardia in post-myocardial infarction rabbit hearts is phase dependent and that multiple monophasic shocks over the ventricular tachycardia cycle rather than biphasic shocks are responsible for unpinning of reentry leading to self-termination. The authors used panoramic optical mapping and found that antitachycardia pacing was completely ineffective, while a significant reduction in cardioversion threshold was achieved by applying multiple monophasic shocks within one ventricular tachycardia revolution. Fenton et al. [9] proposed a similar methodology to terminate atrial fibrillation, which the authors termed far-field antifibrillation pacing, by delivering a short train of low-intensity electric pulses at the frequency of antitachycardia pacing but from field electrodes. Using optical mapping in isolated perfused canine atrial preparations, they demonstrated that a series of pulses at low field strength (0.9 to 1.4 V/cm, with only 13% of the energy required for cardioversion) is sufficient to entrain and subsequently extinguish atrial fibrillation with a success rate of 93%.
This has been another exciting year for cardiovascular engineering.
